Quick Answer
Akari Therapeutics Plc reported Stockholders Equity of $28.33 million for fiscal year 2025.
Akari Therapeutics Plc Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $28.33M | +27.4% |
| 2024 | $22.23M | +9807.0% |
| 2023 | -$229.0K | -112.8% |
| 2022 | $1.79M | -67.8% |
| 2021 | $5.55M | -40.8% |
| 2020 | $9.38M | +35.1% |
| 2020 | $6.95M | +16.6% |
| 2020 | $5.96M | +82.3% |
| 2020 | $3.27M | +42919.1% |
| 2019 | $7.6K | -99.8% |
| 2019 | $4.90M | +967.2% |
| 2019 | $459.4K | -90.5% |
| 2019 | $4.84M | +10.8% |
| 2018 | $4.37M | -80.4% |
| 2017 | $22.24M | -34.8% |
| 2016 | $34.10M | -30.0% |
| 2015 | $48.72M | +2091.3% |
| 2014 | $2.22M | +454.9% |
| 2013 | $400.7K | +111.9% |
| 2012 | -$3.36M | -35.2% |
| 2011 | -$2.48M | -24.0% |
| 2010 | -$2.00M | -17.8% |
| 2009 | -$1.70M | -35.2% |
| 2008 | -$1.26M | -1996.7% |
| 2007 | -$60.0K | +87.2% |
| 2006 | -$467.0K | -137.9% |
| 2005 | $1.23M | — |
| 2004 | $0.00 | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $22.69M | +438.9% | -11.4% |
| June 30, 2025 | $25.61M | +791.5% | +17.7% |
| March 31, 2025 | $21.75M | +712.0% | -2.2% |
| December 31, 2024 | $22.23M | +9807.0% | +432.1% |
| September 30, 2024 | -$6.69M | -3242.7% | -80.8% |
| June 30, 2024 | -$3.70M | -233.2% | -4.2% |
| March 31, 2024 | -$3.55M | -154.2% | -1451.5% |
| December 31, 2023 | -$229.0K | -112.8% | -207.5% |
- Akari Therapeutics Plc showed an increase of +27.4% in Stockholders Equity compared to the prior fiscal year.
- The most recent figure is from Akari Therapeutics Plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: